Form 4: Serina Therapeutics Director Steven Mintz Reports Share Purchases
SEC Form 4 Filing
Director Steven Mintz reports multiple purchases of Serina Therapeutics (SER) common stock through indirect ownership.
Summary
- Steven Mintz, a director of Serina Therapeutics, Inc. (SER), reported several transactions involving the company's common stock.
- These transactions occurred between May 17, 2024, and May 21, 2024.
- Mintz acquired shares indirectly through his spouse and adult children.
- The purchases were made at prices ranging from $8.50 to $10 per share.
- The reported transactions also reflect a reverse stock split of 1-for-35.17.
- Mintz directly owns 3,307 shares of common stock after the reverse split.
Sentiment
Score: 6
Explanation: The sentiment is neutral. Insider buying can be seen as a positive signal, but the amounts are not substantial enough to indicate strong conviction.
Positives
- The director's purchases could be interpreted as a positive signal about the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The reported transactions may influence investor sentiment regarding Serina Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | First reported transaction date: Purchase of common stock. |
| 05/20/2024 | Purchase of common stock by spouse and adult children. |
| 05/21/2024 | Purchase of common stock by spouse. |
| 05/23/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.